Short on time? Go straight to the article here.
What’s different about forecasting the uptake of gene therapies?
It’s common knowledge that gene therapies are vastly different from small molecules or biologics. These differences extend to their usage, which in turn impacts how we forecast their uptake. Gene therapies tend to:
- Have high levels of uncertainty around the duration of their effect.
- Deliver exceptional clinical benefit.
- Only be administered once.
These features combine to create a very unique usage dynamic that needs to be forecasted.
How do I forecast the uptake of gene therapies?
You will be glad to know that there are well-researched techniques for forecasting the uptake of gene therapies. Not only that, but you can also forecast the uptake of the chronic therapies that may be impacted by the launch of a gene therapy.
Our founder and chairman, Gary Johnson, discusses these nuances of forecasting the uptake of cell and gene therapies in an article published in the Foresight journal.
Download the article here.
This material originally appeared in Foresight, Issue 76 (forecasters.org/foresight) and is made available with permission of Foresight and the International Institute of Forecasters.
